Ian F. Parney

Ian F. Parney, M.D., Ph.D., is a Professor of Neurosurgery at Mayo Clinic in Rochester, Minnesota, where he also serves as Vice Chair for Research in the Department of Neurologic Surgery and Mayo Clinic Enterprise Chair for Neurosurgery Research. He is affiliated with the Mayo Clinic Alix School of Medicine and holds a joint appointment in the Department of Immunology. His clinical expertise is in malignant brain tumor surgery, including glioblastomas, metastatic tumors, and meningiomas, with advanced techniques such as awake brain surgery, intraoperative MRI, and laser ablation.

Dr. Parney earned his BSc and MD from the University of Alberta, followed by a PhD in Experimental Surgery, and completed clinical and research fellowships at the University of California, San Francisco. His research is centered on three themes: improving glioma surgery through advanced imaging and guidance, understanding glioblastoma immunology, and developing effective immunotherapies such as dendritic cell vaccines. His lab uses patient-derived models, humanized mice, and collaborations with the Mayo Clinic Human Cellular Therapy Laboratories for GMP-grade vaccine production.

His research publications span neuro-oncology, immunology, and surgical innovation, with a strong translational focus. He actively leads national clinical trials and is deeply involved in education, mentoring students, residents, and fellows. He holds leadership roles in major professional societies, including the American Association of Neurological Surgeons (AANS) and Society for Neuro-Oncology.

• Listed in Who's Who in America
• Best Doctors in America
• Best Doctors in Canada
• Governor General's Gold Medal for Top PhD Graduate
• New Investigator Award
• Multiple research fellowships and bursaries

Dr. Parney is actively involved in clinical trials, grant-funded research, and national committees, including the National Cancer Care Network CNS Panel. His lab operates at the intersection of surgery and immunology, aiming to improve outcomes for patients with glioblastoma. He is a member of multiple research groups, including the David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Program.